Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026)
Maze Therapeutics (MAZE) posted Cash from Investing Activities of $6.3 million for Q1 2026, up 106.07% sequentially from -$103.4 million in Q4 2025, and up 2198.66% YoY from $272984.9 in Q1 2025.
Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at $6.3 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 2198.66% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$164.4 million (down 13986.38% YoY) and the FY2025 annual result came in at -$171.0 million, down 14805.14% from the prior year.
- Cash from Investing Activities improved to $6.3 million in Q1 2026 per MAZE's latest filing, from -$103.4 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $6.3 million in Q1 2026 and troughed at -$103.4 million in Q4 2025.
- A 3-year average of -$18.4 million and a median of -$299000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities tumbled 64834.95% in 2025, then jumped 2198.66% in 2026.
- Over 3 years, Cash from Investing Activities stood at -$605000.0 in 2024, then sank by 16988.76% to -$103.4 million in 2025, then soared by 106.07% to $6.3 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $6.3 million, -$103.4 million, and -$66.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -128.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -128.51 Mn |
| Jun 30, 2026 | -128.51 Mn |
| Mar 31, 2026 | 6.28 Mn |
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | -103.39 Mn |
| Dec 31, 2025 | -103.39 Mn |
| Sep 30, 2025 | -66.88 Mn |
| Sep 30, 2025 | -66.88 Mn |
| Jun 30, 2025 | -393,000.00 |
| Jun 30, 2025 | -393,000.00 |
| Mar 31, 2025 | -299,000.00 |
| Mar 31, 2025 | -299,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | -103,000.00 |
| Sep 30, 2024 | -103,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Mar 31, 2024 | -279,000.00 |
| Mar 31, 2024 | -279,000.00 |